Touted as a breakthrough of sorts in the U.S. healthcare and medical devices industry, the Southern Utah University (SUU) has teamed up with the cancer diagnostics market pioneer LUMEA, Inc. Reportedly, the latest partnership aims to vigorously accentuate the pace of enhancing cancer diagnostics in the arena of pathology.
Apparently, LUMEA plans to sponsor Digital Diagnostic Medical Research Initiative (DDx-MRI), the research program of SUU, which intends to invite internationally recognized specialists of healthcare and medical devices industry to the university for research sabbaticals. In essence, the latest initiative would provide exceptional research opportunities for SUU students interested in medical research, histology, and engineering domains.
As per reliable sources, the program has been recently initiated with SUU appointing the first research scholar for DDx-MRI, Dr. Sorin Musat. For the record, Dr. Musat is a resident of Romania and a Carol Davila University graduate in anatomical pathology and is known to have developed the initial tissue microarray utilized in clinical diagnostics.
Speaking on the development, Chief Medical Officer and Founder of LUMEA, Dr. Matthew Leavitt was quoted stating that the latest alliance would expand the company’s abilities to improve the prevailing cancer biopsy processes.
For the uninitiated, LUMEA, the Utah based firm was established in 2014 by a renowned Stanford-trained pathologist, Dr. Matthew Leavitt with an ambitious goal to revolutionize diagnostic medicine. The company is known to develop the first integrated biopsy-to-digital diagnostic platform which aims to modernize the tissue handling and pathology processes. The platform has been recognized as an excellent benchmark in healthcare and medical devices industry and has further assisted the company to enable the commercialization of diagnostic artificial intelligence.
Incidentally, the company is known to have undergone severe trials and tribulations career to bring about a massive transformation in standardizing the diagnostic practices followed across the cancer diagnostics industry.
